Almirall 2011 outlook poorer than expected
This article was originally published in Scrip
Executive Summary
Pricing pressures and austerity measures took their toll on the Spanish pharmaceutical company Almirall and its 2010 net sales and income, as expected in the firm's previous guidance. However, Almirall's outlook for 2011 is below analysts' predictions.